Research output per year
Research output per year
Personal profile
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Fingerprint
Dive into the research topics where Jeroen Hiltermann is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
CT-assessed sarcopenia and immune-related adverse events in patients with lung cancer: A competing risk time-to-event analysis
Suazo-Zepeda, E., Viddeleer, A. R., Maas, W. J., Postmus, D., Heuvelmans, M. A., Hiltermann, T. J. N. & De Bock, G. H., Jan-2025, In: Lung Cancer. 199, 8 p., 108054.Research output: Contribution to journal › Article › Academic › peer-review
Open AccessFile9 Downloads (Pure) -
Immune checkpoint inhibitor-mediated polymyalgia rheumatica versus primary polymyalgia rheumatica: comparison of disease characteristics and treatment requirement
Vermeulen, O. C. B., Brouwer, E., Slart, R. H. J. A., Sandovici, M., Rutgers, A., Hilterman, T. J., Hiddinga, B., Oosting, S. F., Jalving, M., de Heij, A. H., Knapen, D. G., Hospers, G. A. P. & van der Geest, K. S. M., Feb-2025, In: Rheumatology (Oxford, England). 64, 2, p. 771-779 9 p.Research output: Contribution to journal › Erratum
Open AccessFile4 Citations (Scopus)33 Downloads (Pure) -
Novel immune checkpoint inhibitor strategies in advanced non-small cell lung cancer: towards biomarker-driven therapies?
Muntinghe-Wagenaar, B. B. & Hiltermann, T. J. N., 28-Feb-2025, In: Translational lung cancer research. 14, 2, p. 328-333 6 p.Research output: Contribution to journal › Editorial › Academic › peer-review
Open AccessFile15 Downloads (Pure) -
Quality of life, neurocognitive functioning, psychological issues, sexuality and comorbidity more than 2 years after commencing immune checkpoint inhibitor treatment
Candido, W., Eggen, A. C., Jalving, M., Bosma, I., Horinga, R. D., van Heuvelen, K. C., Hiltermann, T. J. N., Oosting, S., Racz, E., van der Klauw, M. M., Reyners, A. K. L. & Nuver, J., 28-Mar-2025, In: Journal for immunotherapy of cancer. 13, 3, 13 p., e011168.Research output: Contribution to journal › Article › Academic › peer-review
Open AccessFile -
Real-world 5-year survival outcomes with durvalumab after chemoradiotherapy in unresectable, stage III NSCLC: Final data extraction from PACIFIC-R
Girard, N., Bar, J., Daniel, C., Field, J., Fietkau, R., Garassino, M. C., Lopez, P. G., Haakensen, V. D., Hiltermann, J. T., Kao, S. C., McDonald, F., Mornex, F., Moskovitz, M. T., Peters, S., Siva, S., Solomon, B., Qiao, Y., Anand, S., Chander, P. & Filippi, A. R., Mar-2025.Research output: Contribution to conference › Poster › Academic
Activities
-
Longkanker screening redt levens, maar is niet genoeg
Hiltermann, J. (Speaker)
31-Jan-2025Activity: Talk and presentation › Professional or public presentation › Professional
File -
Lectures at EMMP Module 7 Immunopathology
Hiltermann, J. (Speaker)
12-Feb-2025Activity: Talk and presentation › Professional or public presentation › Professional
File -
Efficacy and Safety of Rilvegostomig, an Anti-PD-1/TIGIT Bispecific, for CPI-naïve Metastatic NSCLC with PD-L1 1–49% or ≥50%
Izumi, H. (Speaker) & Hiltermann, J. (Contributor)
7-Mar-2025Activity: Talk and presentation › Academic presentation › Academic
-
Molecular Tumor Board: the role in the journey towards treatment decision-making of complex or rare variants
Hiltermann, J. (Speaker), Schuuring, E. (Speaker), Timens, W. (Speaker) & de Jager, V. (Speaker)
12-Feb-2025Activity: Talk and presentation › Professional or public presentation › Professional
File -
Interim analysis of a randomized study of 1L BMS-986012 (anti-fucosyl-GM-1) with Chemotherapy and nivolumab in ES-SCLC
Sugawara, S. (Speaker) & Hiltermann, J. (Contributor)
6-Mar-2025Activity: Talk and presentation › Academic presentation › Academic
Press/Media
-
TLCR Outstanding Author interview
24/02/2025
1 Media contribution
Press/Media: Expert Comment › Professional
-
Rilvegostomig Elicits Responses in CPI-Naive NSCLC, Irrespective of PD-L1 TPS Status
10/09/2024
1 Media contribution
Press/Media: Expert Comment › Popular
-
Terminaal zieke John Franke strijdt met podcast voor bevolkingsonderzoek naar longkanker
01/08/2022
1 Media contribution
Press/Media: Expert Comment › Popular
-
-
EERSTE LONGKANKERPATIËNT BEHANDELD MET GEMODIFICEERDE T-CELLEN Primeur met TCR T-cellen
04/10/2021
2 items of Media coverage
Press/Media: Expert Comment › Popular